Charming Medical Confirms Nasdaq Delisting; Trading Suspends Nov. 9 Absent Appeal
MCTA has more than doubled off its 52-week low of $4.3 on elevated volume (4.9× avg).
Summary
Charming Medical received a Nasdaq delisting determination tied to the 2025 SEC trading suspension; absent an appeal by November 5, 2026, trading halts November 9 and the stock moves to an uncertain OTC market.
Key Events · Legal and Risk Events · MCTA
-
Nasdaq Determines to Delist MCTA
Nasdaq Listing Qualifications Staff issued a delisting determination letter dated October 29, 2026, invoking Listing Rule IM-5101-4, which lets Nasdaq delist a company where third parties may be engaging in misconduct and the SEC has imposed a temporary trading suspension.
-
Root Cause: 2025 SEC Suspension
The SEC suspended trading in the company's securities on November 11, 2025 over potential manipulation through social-media recommendations to buy, hold or sell the stock; Nasdaq halted trading and has now moved to delist.
-
Appeal Deadline and Trading Halt
Unless the company requests an appeal by November 5, 2026, trading is suspended at the opening of business on November 9, 2026, after which Nasdaq will file a Form 25-NSE to remove the securities from listing and registration.
-
No Wrongdoing Finding; OTC Uncertain
The company states Nasdaq has not communicated any finding that it engaged in wrongdoing and that the delisting does not affect business operations or financial condition; post-delisting trading may occur OTC but there is no assurance an active market will develop.
Analysis · MCTA · Industrial Applications And Services
Nasdaq has determined to delist Charming Medical under Listing Rule IM-5101-4, a discretionary authority invoked because the SEC suspended trading in the stock on November 11, 2025 over suspected social-media manipulation. Unless the company appeals by November 5, 2026, trading stops at the open on November 9, 2026 and Nasdaq will file a Form 25-NSE to strip the listing and registration. The company says Nasdaq has made no finding of wrongdoing and that operations are unaffected, but losing the Nasdaq market leaves holders dependent on an OTC market that may never develop real liquidity.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCTA was trading at $29.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $438.5M. The 52-week trading range was $4.30 to $31.70. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.